SLC22A5 and malignant colon neoplasm: Conjugation of PLGA nanoparticles with L-carnitine on the surface targets them to two plasma membrane transporters, OCTN2 and ATB0,+, both of which are expressed at higher levels in colon cancer cells than in normal cells.